Jul 23, 2008
Story Timeline: 82 days
DANBURY, Conn.-- (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) announced today the publication of positive findings from studies demonstrating the superior metabolic profile of VIAject™ ultra rapid-acting insulin compared to the rapid-acting analog, Humalog®, and regular human insulin in healthy volunteers and compared to regular human insulin in patients with type 1 diabetes. The articles appear in the current issues of the journals Diabetologia and Journal of Diabetes Science and Technology. In the Phase I glucose clamp study (Steiner et al., Diabetologia, 2008), ten healthy volunteers received subcutaneous injections of VIAject™ ultra rapid-acting insulin, insulin lispro (Humalog®) or regular human insulin on separate days. The study showed that VIAject™ was absorbed and produced its metabolic effect faster than both...
[read full story]
Your Web Site
